It is also the first trial that has looked in detail at statin effects on ‘upstream’ process at cell and neural system levels, reflecting a pathogenic pathway between gene disruption and the autism-related behavioural psychopathological outcomes known in NF1. This evidence concerns the gene NF1 and autism.